NEW YORK--(BUSINESS WIRE)--IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (PINKSHEETS: SVFC.PK); (“IntelliCell”) or the (“Company”), was invited to demonstrate its stromal vascular fraction technology at the recent Baseball Injuries Symposium at the Andrews Sports Medicine Institute in Alabama held and sponsored by USA Baseball. The course Chairman is Dr. James Andrews, and moderated by PT Kevin Wilk, and Dr. Jeff Dugas. One of the courses presented during the three day event was on stem cell technology presented by Dr. Joshua Hackel. Dr. Hackel presented the state of regenerative medicine technology in the role of treating sports injuries. The link is http://www.mediafire.com/?u7bfa662e3r1sdp.
Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, "We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year."
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioSciences is exploring storing the stromal vascular fraction in cryo-storage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.